Please assess the completion status of the following clinical trial:

Trial Title: A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject diagnosed as having Parkinson's disease in accordance with Diagnostic Criteria established by the Research Committee of MHLW-specified Intractable Neurodegenerative Diseases (1995)~2. Subject is 30 years \< \> 80 years at the time of informed consent~3. Hoehn \& Yahr stage 1- 3~4. Total of each sum score of UPDRS Part 2 and 3 is over 10 at screening test~Exclusion Criteria:~1. Subject has previously participated in a trial with SPM 962~2. Subject is on L-dopa treatment for total of over 6 months at the time of informed consent~3. Subject has psychiatric symptoms, e.g. confusion, hallucination, delusion, excitation, delirium, abnormal behavior at screening test and baseline~4. Subject has orthostatic hypotension~5. Subject has a history of epilepsy, convulsion and other~6. Subject has a complication of serious cardiac disorder/arrhythmia or has the history~7. Subject has arrhythmia and treated with class 1a anti-arrhythmic drugs (e.g. quinidine, procainamide etc.) or class 3 anti-arrhythmic drugs (e.g. amiodarone, sotalol etc.)~8. Subject has serious ECG abnormal at screening i.e.; 1) Subject has more than 450 msec of QTc values both in two measurements at screening test 2) Subject has more than 470 msec for females and more than 450 msec for males of mean QTc values of two measurements at baseline~9. Subject has congenital long QT syndrome~10. Subject has serum potassium of less than 3.5 mEq/L at screening test.~11. Subject has total bilirubin of 3.0 mg/dL and above or AST(GOT), ALT(GPT) greater than 2.5 times (or 100 IU/L and above) of the clinical laboratory's upper limit of the reference range at screening test~12. Subject has 30 mg/dL and above of BUN or 2.0 mg/dL and above of serum creatinine at screening test~13. Subject has a history of allergy to topical medicine, e.g. transdermal patch~14. Subject is pregnant, nursing, or is child bearing potential while the trial~15. Subject is receiving therapy with prohibited drug specified in the study protocol~16. Subject has a history of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplant~17. Subject has dementia~18. Subject is unable to give consent~19. Subject is participating in another trial of an investigational drug or done so within 12 weeks prior to the initial treatment~20. Investigator judges that subject is inappropriate as a study subject with other reasons

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).